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Abstract
Percutaneous coronary intervention (PCI) in coronary artery disease (CAD) with very small vessels remains challenging. 
The aim of this study is to evaluate the safety and effectiveness of the 2.25-mm diameter Ultimaster sirolimus-eluting stent 
in the treatment of Japanese patients with CAD due to lesions in very small vessels. The CENTURY JSV study is a prospec-
tive, multicentre, single-arm study. Seventy patients with lesions deemed suitable for implantation of a 2.25-mm diameter 
stent were enrolled at seven hospitals in Japan. Patients underwent clinical follow-up at 1-, 9-month, 1-, and 2-year after the 
PCI procedure. The primary endpoint was the major adverse cardiac event (MACE), a composite of cardiac death, target 
vessel myocardial infarction (MI), and clinically driven target lesion revascularization (TLR) free rate at 9-month follow-
ing the procedure. The MACE-free rate was 97.1%, and the lower limit of the two-sided 95% confidence interval (CI) was 
90.1%, which exceeded the threshold of 80% set as the performance goal. Angiographic in-stent and in-segment late loss 
at 9-month were 0.22 ± 0.31 and − 0.02 ± 0.34 mm, respectively. Between 9 months and 2 years, two additional TLRs 
occurred. Stent thrombosis, bleeding and vascular complication did not occur throughout 2 years. The 2.25-mm diameter 
 Ultimaster® bioresorbable-polymer sirolimus-eluting stent is safe and effective for treating lesions in very small coronary 
arteries throughout 2 years after stent implantation.
Clinical trial registration: UMIN000012928.
Keywords Drug-eluting stent · Sirolimus · Bioresorbable · Very small vessel
Introduction
Over the history of percutaneous coronary intervention 
(PCI), in the era of plain old balloon angioplasty (POBA) 
and the following period in which bare metal stents (BMS) 
were used, clinical outcomes in small vessels were less 
favorable than those in large vessels and were far from Presented at the EuroPCR 2016 Meeting of the European Society 
of Cardiology, Paris, France, May, 17–20, 2016.
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satisfactory. Pfisterer et al. compared the outcomes between 
drug-eluting stents (DES) and BMS in the treatment of small 
and large vessels based on a 3-year analysis of the BASKET 
study [1], and reported that MACE was significantly more 
frequent with BMS than with DES in small vessels.
Only a few multicenter clinical studies have reported both 
clinical and angiographic outcomes for all enrolled patients 
at follow-up using stents smaller than 2.5 mm in diameter 
[2–7]. There are even fewer studies in which the second-
generation DESs were used [3, 7], and there have been no 
studies that examined 2.25-mm diameter DESs with a biore-
sorbable polymer.
Asian population, including Japanese patients, are physi-
cally smaller than Western patients. In addition, about 40% 
of the Japanese patients undergoing PCI treatment are com-
plicated by the presence of diabetes mellitus. Therefore, the 
coronary arteries to be treated are often narrower in Japanese 
patients than in their western counterparts. Consequently, 
considering that a higher percentage of small-diameter stents 
are used in such patients, it is important to verify the clinical 
outcomes associated with 2.25-mm diameter stents when 
establishing a treatment policy for PCI in Japanese patients.
Considering the situation described above, we conducted 
a multicenter clinical study of the 2.25-mm Ultimaster stent, 
which is a third-generation sirolimus-eluting stent (SES) 
with a bioresorbable polymer, in Japanese patients to evalu-
ate the clinical and angiographic outcomes over a 9-month 
and longer follow-up period.
Methods
Study design and patient population
This study is a prospective, multicentre, single-arm study. 
The study was reviewed and approved by the Institutional 
Review Board of each site and conducted in compliance with 
the Declaration of Helsinki and Good Clinical Practice.
The inclusion/exclusion criteria were as follows.
Patients with ischemic heart disease due to significant 
stenosis in single lesions shorter than 38 mm (single stent 
for target lesion), and suitable for 2.25-mm diameter stent 
implantation were considered for enrollment.
Main exclusion criteria were renal failure requiring dialy-
sis, acute myocardial infarction (AMI) within 48 h, bifurca-
tion lesions requiring stenting of both main and side branch, 
ostial lesions, bypass grafts, left main trunk lesions, staged 
PCI, in-stent restenosis, and lesion requiring preparation 
other than balloon pre-dilation.
Prior to subject enrollment, patients received a full expla-
nation of the study and provided written consent.
Hypothesis
Bare metal stents less than 2.5 mm in diameter were not 
approved, and there was no DES less than 2.5 mm for 
which evaluation was defined in Japan at the start of the 
present study, due to the concern that they were associated 
with high rates of restenosis and a DES has just approved. 
Therefore, we designed the current study to evaluate the 
outcomes of patients treated with the 2.25-mm Ultimas-
ter DES, and the results will be compared with histori-
cal control—POBA. Our hypothesis was that the lower 
limit of the two-sided 95% confidence interval (CI) of the 
MACE-free rate of 2.25-mm diameter Ultimaster stent 
exceeds 80%, which is the 9-month MACE-free rate of 
POBA based on previous study [8].
Sample size calculation
Based on the outcomes reported in DES literature [9–11], 
assuming that the 9-month MACE-free rate of 2.25-mm 
diameter Ultimaster stent is 93% and the lower limit of 
the two-sided 95% CI to be at least 80%; to achieve 80% 
study power, 62 patients are required. Taking into account 
a dropout rate of 10%, we established 70 patients as the 
target sample size.
Study device
The platform of the investigational device is a cobalt-
chromium alloy 2-link, open-cell structure. Sirolimus, 
a drug inhibiting endothelial proliferation, is loaded at 
3.9 μg/mm. The polymer is a poly (d, l-lactic acid)-poly 
(caprolactone) copolymer, which uses abluminal gradient 
coating technology. This polymer is designed to dissolve 
within 3–4 months, and the drug is designed to be gradu-
ally released for about 3 months.
The following 7 stent sizes were used in the present 
study: diameter: 2.25 mm, length: 12, 15, 18, 24, 28, 33, 
and 38 mm.
Procedural and post‑interventional practices
Only patients with a single lesion requiring treatment 
were enrolled. The use of a single stent was recommended 
except in case of bailout. Apart from mandatory lesion 
pre-dilatation, PCI was performed in accordance with the 
standard procedure of each site.
Antiplatelet therapy with aspirin and a P2Y12 inhibi-
tor was started before the index procedure and dual 
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antiplatelet therapy were maintained for 9 months follow-
ing the procedure in all subjects.
Follow‑up, study endpoints, and definitions
Clinical follow-up was performed at 1, 9 months, 1, and 2 
years. Serious adverse events were reported immediately at 
the time known by the investigators and other events were 
checked at each follow-up visit after the procedure. Angio-
graphic follow-up was performed at 9-month follow-up.
The primary endpoint was the MACE-free rate at 9-month, 
and MACE was defined as; cardiac death, target vessel myo-
cardial infarction (MI) [Q and non-Q wave], and clinically 
driven target lesion revascularization (TLR)-free rate. The 
secondary endpoints were: MACE-free rates at 1-year inter-
val and the rates at 1-year interval thereafter until 5 years had 
elapsed from the time the procedure was performed, target 
lesion failure (TLF), target vessel failure (TVF), TLR, target 
vessel revascularization (TVR), cardiac death, and MI (Q- and 
non-Q-wave) were to be evaluated at 1, 9, 12 months, and 
yearly until 5 years (the definition of all endpoints is given in 
supplementary appendix). All endpoint-related events (death, 
MI, revascularization, stent thrombosis, bleeding, and vascular 
complication) were adjudicated by an independent Clinical 
Event Adjudication Committee.
Angiographic endpoints assessed at 9 months after PCI, 
both, in stent and in segment, were: acute gain, minimal 
lumen diameter (MLD), %diameter stenosis, late lumen loss 
(LLL), and binary restenosis rate.
Angiographic images were digitally recorded and 
assessed by Quantitative Angiographic Core Laboratory 
(Japan Cardio Core, Tokyo, Japan). Digital angiograms were 
analyzed offline by experienced personnel using an auto-
mated edge detection system (QCACMS, Medis Medical 
Imaging Systems, Nuenen, The Netherlands).
Statistical analysis method
The main analysis in this study was to verify that the lower 
limit of exact two-sided 95% confidence intervals (CI) of 
the MACE-free rate at 9 months after PCI is more than 80% 
in the full analysis set (FAS). The point estimates and two-
sided 95% CI using exact method were calculated for TLF-, 
TVF-, TLR-, and TVR-free rates. All the analyses were car-
ried out using SAS Release 9.2 (SAS Institute Japan Ltd.).
Results
Baseline and procedural characteristics
A total of 70 patients were enrolled at 7 sites in Japan from 
April 16, 2014 to December 25, 2014. The mean age of 
the patients at the time of PCI was 70.4 ± 9.2 years; con-
comitant diseases including hypertension (87.1%), diabetes 
mellitus (37.1%), lower limb lesions (7.1%), and previous 
MI and PCI were present in 27.1 and 52.9% of the patients, 
respectively, reflecting the standard population of Japanese 
patients undergoing PCI (Table 1). In terms of lesion char-
acteristics, as the target lesions were small-diameter vessels, 
most of them were located in the distal part of the left ante-
rior descending artery and circumflex artery, and bifurcation 
lesions were slightly more prevalent (Table 2). 
The mean lesion length was 14.64 ± 7.58 mm, reference 
vessel diameter was 1.95 ± 0.28 mm, and the post-proce-
dural in-stent MLD was 1.99 ± 0.27 mm. All stents were 
successfully implanted in all patients (Table 3).
Angiographic outcomes
Nine-month follow-up angiography was performed in 69 
patients (98.6%). The MLD was 1.76 ± 0.35 mm, indicat-
ing that sufficient vessel diameter was maintained. In par-
ticular, the proximal edge showed good patency with an 
MLD of 1.93 ± 0.44 mm. In-stent and in-segment LLL at 
9 months were 0.22 ± 0.31 and − 0.02 ± 0.34 mm, respec-
tively (Table 4).
Clinical outcomes
Major adverse cardiac events were observed in 2 patients 
(2.9%) at 9 months after the procedure, giving an 
Table 1  Patient demographics
Number of patients 70
Age (mean ± SD) 70.4 ± 9.2
Gender, male (%) 77.1








Cerebrovascular disease (%) 2.9
Peripheral artery disease (%) 7.1
Congestive heart failure (%) 4.3
Family history of CAD (%) 27.1
Current smoker (%) 11.4
Previous PCI (%) 52.9
Previous CABG (%) 0
Previous MI (%) 27.1
Previous Stroke (%) 11.4
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MACE-free rate (primary endpoint) of 97.1% (Table 5). The 
lower limit of the two-sided 95% CI of the MACE-free rate 
at 9 months was 90.1%, which exceeded the lower limit for 
demonstrating superiority to POBA (80%), indicating bet-
ter outcomes with the 2.25-mm diameter Ultimaster stent 
compared to POBA. The breakdown of MACE was non-Q 
MI in one patient and clinically driven TLR in the other. 
TLF and TVF were observed in 2 patients (2.9%) and 3 
patients (4.3%), respectively. Between 9-month and 2-year 
two TLRs were recorded. MACE rate was 8.6% up to 2-year 
(Fig. 1). There were no instances of stent thrombosis (as 
defined by the Academic Research Consortium): bleed-
ing and vascular complication (as defined by the Bleeding 
Academic Research Consortium) through 2 years. There 
was no device malfunction, such as stent crossing failure or 
fracture (Table 6).
Discussion
The main findings of our study are that 2.25-mm Ultimaster 
DES performed very well in this challenging patient and 
lesion characteristics setting despite being a more difficult 
condition (higher age, higher rate of patients with diabetes, 
smaller reference vessel diameter, and longer lesion) than the 
meta-analysis used for setting performance goal. The rate of 
MACE was very low, with no stent thrombosis nor bleeding 
observed through 2 years.
Our data add further evidence to the performance of this 
new stent with bioresorbable abluminal gradient coating and 
reduced dose of antiproliferative drug.
Differences in clinical outcomes among different 
vessel diameters
van der Heijiden et al. reported 2-year outcomes for the 
DUTCH PEERS (TWENTE II) trial conducted using Reso-
lute and Promus everolimus-eluting stents (EESs). It was 
shown that MACE and TLF were significantly more fre-
quent in vessels < 2.5 mm in diameter than in larger ves-
sels [MACE: 10.8 vs. 6.8% (Padj = 0.03), TLF: 9.5 vs. 5.4% 
(Padj = 0.02)] [12]. More detailed analysis revealed no 
significant differences between vessels of < 2.25 vs. 2.25 
to < 2.5-mm, and between those of 2.5 to < 2.75 vs. ≥ 3.0-
mm in diameter. Therefore, a vessel diameter < 2.5-mm may 
be regarded as a threshold for predicting clinical outcomes. 
The results of this study are particularly relevant, because 
it is an all-comer study and as such, representative of daily 
practice. These results show that even when DES are used, 
Table 2  Lesion/procedural characteristics
a Moderate + severe
Number of lesions 70














Stent length (mean ± SD) (mm) 21.4 ± 8.2
Post-dilatation (%) 75.7
Overlapping (%) 2.9
%DS < 30 after PCI (visually) (%) 98.6
Table 3  Baseline and follow-up angiographic data
Number of patients 70
Number of lesions 70
Before procedure
 Lesion length (mm) 14.64 ± 7.58
 Reference vessel diameter (mm) 1.95 ± 0.28
 Minimal lumen diameter (mm) 0.67 ± 0.23
 Diameter stenosis (%) 65.5 ± 9.9
In stent In segment
After procedure
 Minimal lumen diameter (mm) 1.99 ± 0.27 1.57 ± 0.38
 Diameter stenosis (%) 11.7 ± 8.70 29.7 ± 11.7
 Acute gain (mm) 1.31 ± 0.29 0.89 ± 0.36
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treatment of very small vessels can still be challenging 
depending on patient and lesion-specific characteristics.
Similar to Heijiden et  al., Wöhrle et  al. reported the 
clinical outcomes for two stent types, wherein the diam-
eter of small vessels was also subdivided into three catego-
ries < 2.0, 2.0–2.25, and 2.25–2.5 mm [13]. When clinical 
outcomes were evaluated for Ultimaster SES and Xience 
EES, no difference between the two stents was found. The 
event rate in the study for both stents was in line with Hei-
jiden et al., but higher than in our current study. CENTURY 
II was also a study with very limited exclusion criteria, and 
therefore, when interpreting results of the current single-
arm study, it is important to consider differences in patient 
characteristics.
Yeung et al. reported the outcomes for the subset of 
patients treated with 2.25-mm Resolute stent from the RES-
OLUTE US trial [10]. The 12-month TLF rate was 4.8%. 
Similar to our study, Saito et al. [8] reported results of the 
RESOLUTE Small Vessel Study that evaluated Resolute 
in Japanese patients (RESOLUTE Japan SV study). There 
were some differences of patient and lesion characteristics 
between CENTURY JSV study and RESOLUTE Japan SV 
study. Rate of IDDM was significantly higher in RESO-
LUTE Japan SV study (10.8 vs. 0%); in the other hand, ratio 
of B2 and C in lesion classification was higher in CEN-
TURY JSV study (68.6 vs. 45.1%). There is no difference in 
other characteristics (Tables 7, 8). The MACE rate through 
2 years was 12.3% which was similar to our results (8.6%), 
and importantly, in both studies, TLR rate was exception-
ally low (Fig. 2). Although the stenosis and even occlusion 
of small vessels would cause less angina complaints, due 
to the small portion of myocardium supplied by those ves-
sels and as such, less frequently require repeat revasculari-
zation, in the case of angiographic follow-up, the rate of 
Table 4  Angiographic outcomes at 9 months
Number of lesions 69






Binary restenosis rate (%)
 In stent 4.3
 In segment 7.2
Late lumen loss (mm)
 In stent 0.22 ± 0.31
 In segment − 0.02 ± 0.34
Table 5  Primary outcomes at 9 months
MACE cardiac death, a composite of cardiac death, target vessel myo-
cardial infarction (MI), and clinically driven target lesion revasculari-
zation (TLR)






70 68 97.1 90.1–99.7
Fig. 1  Kaplan–Meier curve of MACE-free rate up to 2  years after 
implantation of Ultimaster φ2.25 mm stent
Table 6  Clinical outcomes at 9 months and at 2 years
TLF cardiac death that cannot be clearly attributed to a vessel other 
than the target vessel, target vessel MI, and clinically driven target 
lesion revascularization, TVF cardiac death that cannot be clearly 
attributed to a vessel other than the target vessel, target vessel MI, and 






Death 0 (0%) 0 (0%)
 Any cause 0 (0%) 0 (0%)
 Cardiac 0 (0%) 0 (0%)
MI 1 (1.4%) 3 (4.3%)
 Q MI 0 (0%) 0 (0%)
 Non-Q MI 1 (1.4%) 3 (4.3%)
Clinically driven TLR 1 (1.4%) 3 (4.3%)
Clinically driven TVR 2 (2.9%) 5 (7.1%)
MACE 2 (2.9%) 6 (8.6%)
 Death 0 (0%) 0 (0%)
 Q MI 0 (0%) 0 (0%)
 Non-Q MI 1 (1.4%) 3 (4.3%)
Clinically driven TLR 1 (1.4%) 3 (4.3%)
TLF 2 (2.9%) 4 (5.7%)
TVF 3 (4.3%) 6 (8.6%)
Stent Thrombosis 0 (0%) 0 (0%)
Bleeding 0 (0%) 0 (0%)
Stent fracture 0 (0%) 0 (0%)
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Table 7  Patient demographics 
of CENTURY JSV and 
RESOLUTE Japan SV
P value; χ2 test
CENTURY JSV (N = 70 
patients)
RESOLUTE Japan SV 
(N = 65 patients)
P
Age (mean ± SD) 70.4 ± 9.2 69.4 ± 9.5 –
95% confidence interval 68.2–72.6 67.0–71.8
Gender, male (%) 77.1 67.7 0.30
Type of angina (%) –
 Stable 87.1 –
 Unstable 5.7 –
 Silent ischemia 7.1 –
Diabetes (%) 37.1 41.5 0.73
 IDDM (%) 0 10.8 0.015
Hypertension (%) 87.1 87.7 1.0
Dyslipidemia (%) 87.1 80 0.37
Cerebrovascular disease (%) 2.9 – –
Peripheral artery disease (%) 7.1 – –
Congestive heart failure (%) 4.3 – –
Family history of CAD (%) 27.1 – –
Current smoker (%) 11.4 9.2 0.89
Previous PCI (%) 52.9 67.7 0.11
Previous CABG (%) 0 – –
Previous MI (%) 27.1 32.3 0.64
Previous Stroke (%) 11.4 13.8 0.87
Table 8  Lesion characteristics 
of CENTURY JSV and 
RESOLUTE Japan SV
P value; χ2 test
a Percentage to the total number of patients
b Moderate + severe
CENTURY JSV (N = 70 
patients)
RESOLUTE Japan SV 
(N = 65 patients)
P
Number of lesions 70 71





Lesion classification (%) –
 A 8.6 –
 B1 22.9 –
 B2 35.7 45.1 0.008
 C 32.9
Bend (> 45°) (%) 8.6 – –
Calcificationb (%) 7.1 – –
Tortuosityb (%) 24.3 – –
Bifurcation (%) 21.4 – –
Stent length (mean ± SD) (mm) 21.4 ± 8.2 19.25 ± 5.98
95% Confidence interval 19.4–23.4 17.84–20.67
Post-dilatation (%) 75.7 73 0.89
Overlapping (%) 2.9 – –
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revascularization is shown to be higher. In the current study, 
there was two (2.9%) TLRs between 9 months and 2 years, 
further confirming excellent antiproliferative feature of those 
new generation DES.
To verify whether the clinical outcomes of Ultimaster 
are affected by the stent diameter, we compared the results 
from the present study with those of the CENTURY II study, 
a pivotal study of Ultimaster stents that used stents with 
a diameter of 2.5–4.0 mm [14]. The CENTURY II study 
included an all-comer cohort (cohort B) and a cohort with 
more restrictive inclusion criteria compliant with Japanese 
regulations (cohort JR). Since inclusion criteria in CEN-
TURY JSV trial were more similar to cohort JR, we com-
pared our findings with the outcomes of this population. 
Despite some differences in overall risk factors in the two 
studies, the clinical outcomes were similar, with TLF rates 
in current study of 5.7% and in CENTURY II 5.5% (Fig. 3). 
This finding reassures stable performance of Ultimaster DES 
across the wide patients and lesions characteristics, vessel 
size, as well as geographic areas. Thin struts, high flexibility, 
and conformability to the vessel wall of Ultimaster DES, 
along with bioresorbable polymer are features that alone or 
in synchrony could contribute to those promising findings.
Long‑term benefits of bioresorbable polymer
Several studies have reported the outcomes of (first or sec-
ond generation) DESs in small vessels. Most of these stud-
ies were conducted using durable-polymer DESs, and the 
reported MACE rates at 2 years were about 10–20% for 
first-generation DESs and about 10% for second-generation 
DESs. Although these outcomes were largely satisfactory, 
over a prolonged period, the remaining polymer has been 
shown to induce inflammation associated with excessive cor-
onary artery contractions and the development of vasa vaso-
rum. It has been suggested that these long-term events may 
be preventable using a bioresorbable-polymer DES, which 
eventually becomes a BMS, because inflammation due to 
Fig. 2  Comparison of clinical 
outcomes at 9 months and 2 
years with RESOLUTE φ2.25 
mm
Fig. 3  Comparison of clinical 
outcomes at 9 months and 2 
years with other sizes of Ulti-
master DES
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the polymer is reduced after the polymer disappears [15, 
16]. Regarding outcomes for bioresorbable-polymer DESs, 
Wöhrle et al. have reported the results of vessels ≤ 2.5 mm 
in diameter as a subgroup analysis of the CENTURY II 
trial. These comprised an RCT of bioresorbable-polymer 
DES (Ultimaster) and durable-polymer DES (Xience) [13]. 
They found that the 12-month TLF was similar between the 
bioresorbable-polymer DES (6.9%) and durable-polymer 
DES (7.7%).
In the present study, although in a small sample size, the 
incidence of MACE during the initial 9 months was low 
at 2.9%, and the angiographic in-stent late lumen loss was 
also low (0.22 mm). This effect may be due to the polymer 
resorption and drug release time being both 3–4 months. 
As such drug can suppress inflammation potentially caused 
by polymer degradation, leaving only thin bare metal stent 
embedded into newly formed intima, as shown in serial opti-
cal frequency domain imaging [17]. However, to clarify the 
benefit of bioresorbable-polymer DES for the treatment of 
very small vessels, further examination of long-term out-
comes is necessary.
Study limitations
Although strictly monitored and well controlled, CENTURY 
JSV is a small single-arm study. Consequently, it is difficult 
to make comparisons with other stents that can only be done 
in the randomized studies.
The reported follow-up period was relatively short not 
allowing to fully explore potential benefit of bioresorbable 
polymer; however, follow-up of the enrolled patients in this 
study will continue until 5-year allowing the assessment of 
long-term outcomes.
Lesions treated were small diameter, so ischemic symp-
tom might be relatively weak. It may have overestimated the 
performance of this stent.
As this study enrolled Japanese patients only, routine pro-
cedures and medications may be different from those used 
in other regions.
Conclusions
From 2-year result of CENTURY JSV study, the 2.25-mm 
diameter  Ultimaster® bioresorbable-polymer sirolimus-
eluting stent was found be safe and effective for the treat-
ment of lesions in very small coronary arteries in Japanese 
population.
To confirm the effectiveness of the bioresorbable polymer 
compared with a durable-polymer DES, it is necessary to 
obtain the long-term results from a randomized controlled 
trial.
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